Drug Profile
IMC TR1
Alternative Names: LY3022859Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ImClone Systems
- Developer Eli Lilly and Company
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Transforming growth factor beta type II receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV)
- 31 Jul 2012 Phase-I clinical trials in Solid tumours in USA (IV)